Novo’s GLP-1 ad blitz shows where direct marketing is headed next

The newest lesson from the weight-loss drug wars is not just that pharmaceutical companies are spending heavily. It is that direct marketing is becoming a full-funnel business, where TV spots, social campaigns, cash-pay offers, telehealth partnerships, and regulatory risk now travel as a pack.

Novo Nordisk spent about $487 million on U.S. advertising for Wegovy and Ozempic in the first nine months of 2025, according to MediaRadar data reported by Reuters. Eli Lilly spent about $214 million on Zepbound and Mounjaro in the same period, which means Novo outspent its main rival by more than two to one. The brand-by-brand breakdown was even starker: $316 million for Wegovy, $169 million for Ozempic, $131 million for Zepbound, and $83 million for Mounjaro.

That kind of spending would be notable in any category. In direct marketing, it is a flare. It shows how fast the GLP-1 market has shifted from a supply-constrained product story to a demand-shaping one. Reuters reported that Novo pulled back on ads during shortages in 2024, then ramped them up again once supply improved in 2025. That is classic direct-marketing behavior: when inventory opens up, the machine turns back on.

But the more interesting part is what happened next. Novo’s own executive vice president of U.S. operations told Reuters the company planned to advertise its new pill version of Wegovy immediately and push sales through cash-pay, direct-to-consumer channels, partly because insurance coverage is uneven. That line matters. It means the campaign is not just about awareness. It is about shortening the path from interest to purchase, a move that makes pharmaceutical marketing look more like modern ecommerce.

Then came the regulatory splash of cold water. On March 3, Reuters reported that the FDA had warned Novo Nordisk for the second time in less than a month over misleading advertising, saying an Ozempic consumer ad made false or misleading claims about the drug’s benefits and implied superiority over other GLP-1 medicines. Reuters also reported that, on the same day, the FDA sent 30 warning letters to telehealth firms over misleading marketing of compounded GLP-1 drugs. That is a pretty vivid reminder that the more aggressive direct marketing becomes, the more likely regulators are to show up with a flashlight and a clipboard.

There is another direct-marketing twist here: distribution is becoming part of the campaign. Reuters reported that Novo struck a deal with Hims & Hers to sell FDA-approved Wegovy and Ozempic through the telehealth platform, ending a legal fight over compounded versions. For marketers, that is the real signal fire. The winning model is no longer just “run the ad and hope the doctor conversation follows.” It is increasingly “run the ad, control the offer, simplify the path, and make checkout feel as frictionless as possible.”

That is why this story matters well beyond pharma. Direct marketers in every category should pay attention to the structure of what Novo and Lilly are doing. The campaign is not just creative. It is inventory-aware, channel-aware, compliance-sensitive, and conversion-minded. It also shows the danger of trying to out-charm the facts. Reuters reported that the FDA objected not only to the claims in Novo’s Ozempic ad but also to the ad’s comedic treatment of rival drugs, saying it created the impression that competing medicines lacked meaningful benefits. In other words, brand voice is still subject to reality.

The broader takeaway is deliciously uncomfortable. Direct marketing is getting more powerful at exactly the same moment it is getting less forgiving. Marketers now have more tools to create demand, personalize offers, and collapse the distance between ad and sale. They also have less room to get sloppy, vague, or overconfident. Novo’s spending surge shows what a modern direct-marketing blitz looks like. The FDA warnings show the bill can arrive fast if the funnel outruns the facts.